Version 2 of the TruSight Oncology 500 tissue research-use-only assay is currently under development, the company said, with a global release set for mid-2025.

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino effect of leadership changes.

Pfizer has been tapped by Shanghai-based Zai Lab to help market the company’s antibacterial drug Xacduro in mainland China. The companies did not disclose the financial terms of the deal, which is slated to run through November 2028. The team-up comes as other drugmakers, like Merck, J&J and AstraZeneca, face challenges in the country.

After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for chapter 11 bankruptcy.

New York-based health comms agency Calcium+Company is living up to its name, strengthening the bones of its business with the creation of a new division.

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the United States, its baby power problems are only just beginning in the U.K. A British law firm representing 1,900 talc claimants has sent a letter to J&J, giving advance notice of a group-action lawsuit that it plans to file in the High Court in London, according to reports.

Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral probiotic yeast to do the work for them, with the fungal cells able to release immune checkpoint inhibitors that shrank intestinal tumors in mice with colorectal cancer.